Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otx-008 SCHEMBL28666062 | 1.00 | LGALS1 (1.00) | LGALS1POLBMAPTCD69ALDH1A1 | |
| SCHEMBL13992476 | 0.77 | LGALS1 (0.63) | LGALS1POLBMAPTALDH1A1CASP2 | |
| SCHEMBL16384637 | 0.74 | ALDH1A1 (0.63) | LGALS1POLBMAPTALDH1A1NPSR1 | |
| SCHEMBL14213201 | 0.73 | LGALS1 (0.57) | LGALS1POLBMAPTALDH1A1NPSR1 | |
| SCHEMBL12986625 | 0.72 | ALDH1A1 (0.57) | LGALS1POLBMAPTALDH1A1CASP2 | |
| SCHEMBL13462776 | 0.72 | CYP1A2 (0.63) | LGALS1POLBALDH1A1CASP2NPSR1 | |
| SCHEMBL16269093 | 0.71 | LGALS1 (0.55) | LGALS1POLBMAPTALDH1A1NPSR1 | |
| SCHEMBL10046739 | 0.71 | LGALS1 (0.55) | LGALS1POLBMAPTALDH1A1CASP2 | |
| SCHEMBL13992489 | 0.71 | LGALS1 (0.55) | LGALS1POLBMAPTALDH1A1CASP2 | |
| SCHEMBL13439306 | 0.71 | LGALS1 (0.55) | LGALS1POLBMAPTALDH1A1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228801-A1 | USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | Institute of Basic Medical Sciences, CAMS (CN) | 2025-07-17 | — | — | US | claimed |
| WO-2025128913-A1 | INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | claimed |
| CN-117860896-A | Application of Galectin-1 inhibitor in preparation of medicines for treating pulmonary fibrosis | 中国医学科学院基础医学研究所 | 2024-04-12 | — | — | CN | claimed |
| CN-116370445-A | Application of OTX008 in osteoporosis diseases | 上海建工医院 | 2023-07-04 | — | — | CN | claimed |
| US-12636341-B2 | Galectin-targeting immunotherapy | VLP THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137696-A1 | Compositions Comprising an Inhibitor of Galectin-3 | UNIVERSITY OF LIVERPOOL (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4739296-A1 | COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3 | University of Liverpool (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739319-A1 | COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3 | University of Liverpool (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-121818590-A | Application of OTX008 in treating HSV-1 virus infection | 上海市公共卫生临床中心 | 2026-04-10 | — | — | CN | disclosed |
| CN-121818590-A | Application of OTX008 in treating HSV-1 virus infection | 上海市公共卫生临床中心 | 2026-04-10 | — | — | CN | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11319374-B2 | Inhibitors of prototypic galectin dimerization and uses thereof | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2022-05-03 | — | — | US | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | LGALS1 4043/4885POLB 2029/4885MAPT 99/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | LGALS1 4523/4885POLB 2350/4885MAPT 9/4885 |
| US-12636341-B2 | Galectin-targeting immunotherapy | LGALS1, LGALS3, LGALS9 | LGALS1 1/4885POLB 4374/4885MAPT 373/4885 |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | LGALS1 393/4885POLB 4618/4885MAPT 2594/4885 |
| US-20260137696-A1 | Compositions Comprising an Inhibitor of Galectin-3 | LGALS3, LGALS1, LGALS2 | LGALS1 2/4885POLB 4763/4885MAPT 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.